WO1997001347A1 - Pharmaceutical composition for wound healing - Google Patents
Pharmaceutical composition for wound healing Download PDFInfo
- Publication number
- WO1997001347A1 WO1997001347A1 PCT/GB1996/000756 GB9600756W WO9701347A1 WO 1997001347 A1 WO1997001347 A1 WO 1997001347A1 GB 9600756 W GB9600756 W GB 9600756W WO 9701347 A1 WO9701347 A1 WO 9701347A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- preparation
- extract
- monoterpene
- wound
- εaid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Definitions
- the invention relates to a pharmaceutical preparation having anti-inflammatory and anti ⁇ bacterial activity which has a beneficial effect on the healing of wounds.
- the invention al ⁇ o relates to a method of making such a preparation.
- the invention is concerned with an extract obtained from the Siberian fir, Abies sibericus Ledebur. which contains ethereal oils composed mostly of monoterpene, neutral diterpenes, resin acids and their ethers.
- the extract is processed so as to be artificially enriched in the monoterpene components.
- topical remedies having anti-inflammatory, anti-bacterial and wound healing effects.
- a particularly well-known example is Fucidin gel. This remedy, however, has a number of disadvantages including, for example, a relatively weak, pharmacological effect, some toxicity to the immune system and the need for expensive synthetic chemicals.
- Extracts of the Siberian fir, Abies sibericus Ledebur. are known to have anti-inflammatory, biostimulatory and strengthening activity.
- a remedy having the above activities is described which uses water produced as a by-product in the production process of Abies Sibericus oil, as a basic material in making a pharmaceutical preparation.
- the water contains 1.0 to 1.5 g/1 terpenoids, 0.5 g/1 vitamin A, 2.3 mg/l vitamin C, up to 1% peucidamin and 1.0 to 1.5 g/1 inorganic ions.
- the pharmacological activity of the aforementioned water is relatively weak and this has been explained by its low content of terpenoids.
- Ledebur which has increased anti-inflammatory, anti ⁇ bacterial and wound healing activity because of extension of the raw material base, without the disadvantages of the prior art preparations. It is also an aim of the invention to simplify the method of production of such a preparation.
- the invention provides a pharmaceutical preparation in the form of a concentrate which, when diluted to an appropriate concentration, ha ⁇ anti-inflammatory, anti-bacterial and wound healing activity which preparation comprises a cap ⁇ ular extract of the Siberian fir, Abie ⁇ sibericu ⁇ Ledebur. and the monoterpene compounds from ethereal oils of ⁇ aid capsular extract, ⁇ aid monoterpene compound ⁇ being pre ⁇ ent in an amount of about 0.1% to about 1.0% by volume.
- the monoterpene compounds are pre ⁇ ent in an amount of 0.5% by volume.
- the preparation ⁇ of the invention are hereinafter referred to by the name Abi ⁇ il.
- a lipophilic solvent such as a vegetable oil is the most preferred diluent, for example, sunflower oil.
- Preparations of the invention which are diluted in this way are hereinafter referred to as Abisil-1.
- the concentrated preparation is diluted with vegetable oil such that the ratio of preparation to oil i ⁇ 1:4.
- the invention provide ⁇ a method of preparing a pharmaceutical preparation which compri ⁇ e ⁇ the ⁇ tep ⁇ of:
- the method above typically compri ⁇ e ⁇ the further step of diluting the preparation of step (d) with a vegetable oil, preferably in a volumetric ratio of preparation to oil of 1:4.
- Temperatures between 10 and 20°C are optimal for mixing the monoterpene-containing di ⁇ tillate with the cap ⁇ ular extract because, although increasing the temperature speeds up the dis ⁇ olution of monoterpene in the extract, it al ⁇ o increases possible losse ⁇ of these light components due to evaporation.
- Mixing with a lipophilic solvent is also preferably carried out at room temperature to avoid evaporation of the light components and therefore inactivation of the final product.
- the monoterpene component of the preparation of the invention includes compounds such as tricylene, limonene, camphene and others.
- Example 1 The preparation of the invention has been shown, when applied to wounds over a 7-10 day period, to produce fast cleansing of the wound from purulent di ⁇ charge and necrotic ma ⁇ ses and to stimulate reparative processes when applied during phase ⁇ I and II of the wound healing process while at the same time being of low irritancy.
- the ⁇ e are not typical properties for known wound healing preparations. The invention will now be described with reference to the following examples.
- Example 1 The invention will now be described with reference to the following examples.
- the capsular extract obtained from Abie ⁇ ⁇ ibericu ⁇ Ledebur. i ⁇ a complex mixture of biologically active ethereal oil ⁇ , ethereal acid ⁇ and their e ⁇ ter ⁇ . It wa ⁇ obtained by needle puncture of subcortical capsules and collection of the exudate. The extract was filtered at room temperature to give an amber coloured, viscous liquid.
- IRV MA ⁇ 3400.2900-, 1740, 1690-1700,
- Anti-inflammatory and wound healing activity were tested on 365 rabbits with a body weight of 2.5-3kg for estimation of Abisil-1 obtained as de ⁇ cribed above.
- the preparation described in Example ⁇ 1,2 and 3 was compared against Fucidin Gel or Sea Buckthorn Oil.
- a portion of dorsal skin was removed (diameter 304cms) .
- the wounds were then infected with 2 x IO 9 micro organisms per ml of Staphylococcus aureus (STAM type) .
- STAM type Staphylococcus aureus
- the wounds were infected with 5 x IO 9 Klebsiella organisms per ml (type K Pneumoniae 1-2 AC) .
- Treatment was started at the time of making the infected wound (2-3 days after infection) .
- the preparation was applied on the clean wound twice daily for ten day ⁇ in a quantity of lml of Abi ⁇ il-1 (in three concentrations) , Sea Buckthorn Oil or lg of Fucidin Gel.
- the ⁇ ucce ⁇ s of treatment wa ⁇ evaluated using bacteriological and clinical observation ⁇ .
- the dynamic ⁇ of local purulent inflammatory effect ⁇ (oedema, hyperae ia, infiltration of - 7 -
- n no. of microbes grown in the Petri dish
- the area of healed wound was determined a ⁇ a percentage according to the formula
- the wound ⁇ were purulent with an area of about 100cm 2 , and were characterised by edematou ⁇ , infiltrated edge ⁇ and hyperaemia of the ⁇ urrounding skin.
- the base of the wound was covered with a deposit of fibrin and had regions of necrosis and purulent discharge.
- the heated area (%) of the wound on day 17 was 90.5 + 5.4 in Group 1 against 53.3 + 5.1 in Control and 78.7 + 6.1 in Group 2 (Fucidin Gel).
- profibroblast ⁇ On day 17 in a group of animals treated with Abisil, the young cells of granulation tissue appeared: profibroblast ⁇ , fibrobla ⁇ t, polybla ⁇ t macrophage ⁇ . No microbial bodie ⁇ , single neutrophil ⁇ .
- the wounds were purulent with an area of about 110cm 2 , and were characterised by edemaous, infiltrated edge ⁇ , and hyperaemia of the ⁇ urrounding ⁇ kin.
- the base of the wound was covered with a depo ⁇ it of fibrin and had regions of necrosi ⁇ and purulent di ⁇ charge. - 14 -
- the wound wa ⁇ covered with a secondary crust and contraction of the wound incomplete.
- the wound was completely epitheliali ⁇ ed, a ⁇ car formed and at the edge ⁇ of the wound, hair growth had occurred.
- Cytological study of wound exudate of animals treated with Abisil on days 4-6 showed 70% of neutrophils together with macrophages, lymphocytes and fibroblasts. A proportion of the microbes were located inside cells.
- the wound ⁇ were purulent with an area of about 110cm 2 and were characteri ⁇ ed by edematou ⁇ , infiltrated edges and hyperaemia of the surrounding ⁇ kin.
- the base of the wound was covered with a deposit of fibrin and had regions of necrosis and purulent discharge.
- Tables 2 and 3 show that on day 17, % of wound healing was 94.3 + 0.1 + 5.1 in control and 78.7 + 6.1 in the group treated with Fucidin gel. Microbe count ⁇ howed a low number of microbe ⁇ already on day 6: 1.4 x 10* against 4.8 x IO 6 in control and 3.5 x 10* in Fucidin-treated group. Cytological study on day 12 or treatment with Abi ⁇ il-1 ⁇ howed an abundance of profibroblast ⁇ , polybla ⁇ t ⁇ and macrophages. The number of neutrophils decrea ⁇ ed to 44%. No microbe cell ⁇ were found.
- Diagno ⁇ i ⁇ erysipelatous inflammation of right femur, bullous-necrotic form of plegmone of the right lower extremity.
- the efficiency of treatment with Abi ⁇ il-1 was high: fast cleaning, granulation and epithelialisation of the wound wa ⁇ ob ⁇ erved. No ⁇ ide effects.
- Thu ⁇ a comparative ⁇ tudy of anti-inflammatory and wound-healing activity which took into account a clinical picture of the inflammatory proce ⁇ and wound healing, microbe count from purulent wounds, time of wound healing and cytological ⁇ tudie ⁇ of the wound-healing proce ⁇ ⁇ howed that the propo ⁇ ed preparation Abi ⁇ il-1 (vegetable oil ⁇ olution of cap ⁇ ular extract from Siberian Fir enriched with a fraction of monoterpene ⁇ in the % ratio 19.5:0.
- l:rest is a more active anti-inflammatory and wound-healing preparation (97.5 + 5.4% and 94.3 + 0.1 of wound healing till day 17 of treatment) than other Abi ⁇ il preparation ⁇ with different fractions of monoterpene ⁇ 19.5:0.02: re ⁇ t and 19.5:02: re ⁇ t) - (90.5 + 5.4% and 94.3 ⁇ 0.1% of wound healing till day 17 of treatment) and Fucidin gel (78.6 + 6.1% of wound healing till day 17 of treatment) .
- an injection into the capsular extract of Siberian Fir of multicomponent fraction of monoterpenes obtained by the fractional separation of capsular extract and a subsequent dis ⁇ olution of enriched capsular extract in vegetable oil allows production of a preparation with high anti-inflammatory, anti-bacterial and wound healing activity.
Abstract
A pharmaceutical preparation is described which has anti-inflammatory, anti-bacterial and wound healing activity and which comprises a capsular extract of the Siberian fir, Abies sibericus Ledebur. and the monoterpene compounds from the ethereal oils of the capsular extract. The monoterpene compounds being present in an amount of about 0.1 to about 1 % by volume. The capsular extract is artificially enriched in the monoterpene components by distilling the natural extract from the capsules of the fir, collecting the light fraction which contains the monoterpene components, reintroducing it back into the original extract and optionally diluting it with a lipophilic solvent.
Description
PHARMACEUTICAL COMPOSITION FOR WOUND HEALING
The invention relates to a pharmaceutical preparation having anti-inflammatory and anti¬ bacterial activity which has a beneficial effect on the healing of wounds. The invention alεo relates to a method of making such a preparation. Specifically, the invention is concerned with an extract obtained from the Siberian fir, Abies sibericus Ledebur. which contains ethereal oils composed mostly of monoterpene, neutral diterpenes, resin acids and their ethers. The extract is processed so as to be artificially enriched in the monoterpene components. There are a number of known topical remedies having anti-inflammatory, anti-bacterial and wound healing effects. A particularly well-known example is Fucidin gel. This remedy, however, has a number of disadvantages including, for example, a relatively weak, pharmacological effect, some toxicity to the immune system and the need for expensive synthetic chemicals.
Extracts of the Siberian fir, Abies sibericus Ledebur. are known to have anti-inflammatory, biostimulatory and strengthening activity. For example, in a USSR patent published in 1993, a remedy having the above activities is described which uses water produced as a by-product in the production process of Abies Sibericus oil, as a basic material in making a pharmaceutical preparation. The water contains 1.0 to 1.5 g/1 terpenoids, 0.5 g/1 vitamin A, 2.3 mg/l vitamin C, up to 1% peucidamin and 1.0 to 1.5 g/1 inorganic ions. The pharmacological activity of the aforementioned water is relatively weak and this has been explained by its low content of terpenoids.
However, attempts to use remedies with higher doses of terpenoids have been unsuccessful due to their toxicity, in particular their embryotoxicity, teratogenic activities and carcinogenic effects. For example, a marked toxic effect has been observed in mice exposed to vapours of Abies Sibericus ethereal oils at a concentration of 4g/m3 for one hour. (Demerion et al, Res (1977) 17(5) 325-329). In addition Abies Sebericus water discussed above contains Δ3 carene which can provoke dermatitis and allergies (Stepanov et al (1972) Transactions of Siberian Branch of the Russian Academy of Science, Biology Series) .
It is the aim of the present invention to produce a preparation using an extract of Abies sibericus
Ledebur. which has increased anti-inflammatory, anti¬ bacterial and wound healing activity because of extension of the raw material base, without the disadvantages of the prior art preparations. It is also an aim of the invention to simplify the method of production of such a preparation.
These aims are satisfied by distilling an extract from the capsules of Abies Sibericus Ledebur. collecting the light, easily distilled fraction which contains the monoterpene compounds of the ethereal oils εuch as tricyclene, limonene and camphene and adding back the distillate to the original extract so that the extract is thereby enriched in monoterpene compounds. It has been found that to produce a preparation having the necessary wound healing activity but low level of toxicity the volumetric ratio of raw extract to the monoterpene-containing distillate is critical.
In accordance with a first aspect the invention provides a pharmaceutical preparation in the form of a
concentrate which, when diluted to an appropriate concentration, haε anti-inflammatory, anti-bacterial and wound healing activity which preparation comprises a capεular extract of the Siberian fir, Abieε sibericuε Ledebur. and the monoterpene compounds from ethereal oils of εaid capsular extract, εaid monoterpene compoundε being preεent in an amount of about 0.1% to about 1.0% by volume. Preferably, the monoterpene compounds are preεent in an amount of 0.5% by volume. The preparationε of the invention are hereinafter referred to by the name Abiεil.
For application to a wound it iε uεually neceεεary that the concentrate be diluted, the level of dilution depending on the moεt εuitable volumetric doεe for the condition in queεtion. In order to enhance uptake of the active componentε of the preparation through the lipid layerε of the skin, a lipophilic solvent such as a vegetable oil is the most preferred diluent, for example, sunflower oil. Preparations of the invention which are diluted in this way are hereinafter referred to as Abisil-1. In a particularly preferred preparation the concentrated preparation is diluted with vegetable oil such that the ratio of preparation to oil iε 1:4. In a εecond aεpect the invention provideε a method of preparing a pharmaceutical preparation which compriεeε the εtepε of:
(a) obtaining an extract from the capεuleε of the Siberian fir, Abieε εibericuε Ledebur.,
(b) filtering εaid extract,
(c) distilling said extract for up to approximately 12 hours and collecting the
diεtillate and,
(d) mixing said distillate with undistilled capεular extract in εuch volumetric amountε aε to produce a preparation in which εaid distillate iε about 0.1 to about 1.0% by volume, preferably about 0.5% by volume.
The method above typically compriεeε the further step of diluting the preparation of step (d) with a vegetable oil, preferably in a volumetric ratio of preparation to oil of 1:4.
Temperatures between 10 and 20°C are optimal for mixing the monoterpene-containing diεtillate with the capεular extract because, although increasing the temperature speeds up the disεolution of monoterpene in the extract, it alεo increases possible losseε of these light components due to evaporation. Mixing with a lipophilic solvent is also preferably carried out at room temperature to avoid evaporation of the light components and therefore inactivation of the final product.
The monoterpene component of the preparation of the invention includes compounds such as tricylene, limonene, camphene and others.
The preparation of the invention has been shown, when applied to wounds over a 7-10 day period, to produce fast cleansing of the wound from purulent diεcharge and necrotic maεses and to stimulate reparative processes when applied during phaseε I and II of the wound healing process while at the same time being of low irritancy. Theεe are not typical properties for known wound healing preparations. The invention will now be described with reference to the following examples.
Example 1
The capsular extract obtained from Abieε εibericuε Ledebur. iε a complex mixture of biologically active ethereal oilε, ethereal acidε and their eεterε. It waε obtained by needle puncture of subcortical capsules and collection of the exudate. The extract was filtered at room temperature to give an amber coloured, viscous liquid.
Physico-chemical analysis was aε follows:
Refractive Index A20 D = 1.512
Density d20 H = 1.0328 g/cm3
IRVMAχ : 3400.2900-, 1740, 1690-1700,
1450, 1390, 1270, 1250, 1040, 900 nm, 800 nm, CM'1
NMR 0.82; 1.67,-4.71;5.77 Mil
Elemental Analyεis C-77.82; H-10.19;S - absent; N - absent
TABLE 1 t
Water Ethanol Acetone Ether Benzene Dioxan Hexane DMSO DMF Chloro form
Raw — + + + + White White — + — material precip precip
Fract- — — + + + + — — — — ion-1
Fract- — + + + + + + — — — ion-2
Residue - 1 + + + + - + - +
- 6a -
1000ml of filtered capsular extract were placed into a diεtillation flaεk and connected to a Volatile Oil Determination apparatuε equipped with a finger condenεer and graduated receiver with tap. The proceεε of distillation continued for 12 hourε. The light, eaεily distilled fraction collected in this way is the ethereal oil which contains monoterpene componentε εuch aε tricyclene, limonene, camphene etc.
0.2ml of monoterpene componentε waε mixed with 195ml of capεular extract at room temperature (18- 20°C) with conεtant stirring. To this mixture was added 804ml of sunflower oil. The reεulting εolution waε then teεted uεing anti-inflammatory, anti¬ bacterial and wound healing teεt methods.
Anti-inflammatory and wound healing activity were tested on 365 rabbits with a body weight of 2.5-3kg for estimation of Abisil-1 obtained as deεcribed above. The preparation described in Exampleε 1,2 and 3 was compared against Fucidin Gel or Sea Buckthorn Oil. In order to obtain a model of experimentally infected wounds a portion of dorsal skin was removed (diameter 304cms) . There was also damage to underlying tisεues. The wounds were then infected with 2 x IO9 micro organisms per ml of Staphylococcus aureus (STAM type) . Additionally the wounds were infected with 5 x IO9 Klebsiella organisms per ml (type K Pneumoniae 1-2 AC) .
Treatment was started at the time of making the infected wound (2-3 days after infection) . The preparation was applied on the clean wound twice daily for ten dayε in a quantity of lml of Abiεil-1 (in three concentrations) , Sea Buckthorn Oil or lg of Fucidin Gel. The εucceεs of treatment waε evaluated using bacteriological and clinical observationε. The dynamicε of local purulent inflammatory effectε (oedema, hyperae ia, infiltration of
- 7 -
surrounding tisεue) quantity and characteriεtics of wound exudate, time of healing and character of granulation, were evaluated microscopically.
Dynamics of elimination of microbes from the wounds waε estimated bacteriologically taking into account the number of microbes in one gram, calculated by the formula H = n x 10 x 10 (or 100 or 1000 depending on the dilution) x K where:
H = no. of microbes in one g of tissue
n = no. of microbes grown in the Petri dish
10 recalculation coefficient
10 recalculation coefficient 100 or 1,000 depending on dilution of material placed on the petri dish
K coefficient of recalculation
Studies were carried out on days 2, 4, 6, 8, 10 after the beginning of treatment
Time of wound healing was determined as:
( . - t2)% t1 x 100, where
t1 iε the time of wound healing in the Control Group (dayε)
t2 time for healing in the Experimental Group (dayε)
- 8 -
The area of healed wound was determined aε a percentage according to the formula
100 x A S
where S iε initial area of the wound in centimetreε2 and A iε the difference in the area of the wound between initial and preεent area at the time of measurement
The efficacy of Abisil (19.5:0.02) in compariεon with reference preparationε was studied in 3 groups of rabbits (6 rabbits per group) . Treatments were:
Group 1 - Abisil
Group 2 - Fucidin gel
Group 3 - Untreated controls
Before treatment, the woundε were purulent with an area of about 100cm2, and were characterised by edematouε, infiltrated edgeε and hyperaemia of the εurrounding skin. The base of the wound was covered with a deposit of fibrin and had regions of necrosis and purulent discharge.
Results
In Group 1 positive dynamics of wound healing were observed on the 2nd day; edema and infiltration of the wound were reduced and hyperaemia had decreased.
In Group 2 (Fucidin gel) signε of inflammation
- 9 -
were clearly visible at this time. A considerable amount of fibrin deposit, thick pus and necrotic tisεue were found at the baεe of the wound.
In the untreated Control Group (Group 3) , abundant purulent diεcharge, haemorrhagic diathesis, edema and hyperaemia were observed at the base and edges of the wound.
On day 8 in the Abisil-treated rabbitε, a significant cleansing of the wound from purulent and necrotic masses was observed.
On day 9 some regionε of marginal epithelialiεation appeared. A similar picture in Group 2 (Fucidin) was observed on dayε 10-12 and in Control Group on day 14.
On dayε 13-14 of observation in the Abisil- treated animals, the base of the wound was completely filled with granulation tissue compared with day 28 in Control Group.
Results are given in Tables 2 and 3 below.
TABLE 2
Anti-inflammatory effect of Abiεil-1 with different content of monoterpene fraction on the model of infected wound
(Staphylococcus + Kiebsiella)
* quantity sufficient to give a total of 100 parts.
TABLE 3
Dynamics of elimination of microbes from purulent wounds in rabbits treated with Abisil-1 Λ (with different content of monoterpene fraction) 3 and Fucidin gel l
Initial m/b Microbe count on day of treatment - Preparation count 2 4 6 8 10 n
Control (untreated) 4.9xl07 2.5X107 5.5xl06 4.8X106 7.1x10s 3.9x10*
Abisil-1 o (19.5:0.02:rest) 4.5xl07 3.7X105 2.1x10* 1.8x10* 1.2X102 0.4X101
Abisil-1 19.5:0.1 rest) .7xl07 3. lxlO5 2.8xlθ4 1.5x10* l.lxlO2 0.2xlθ1
Abisil-1 (19.5:0.2:rest) 4.5xl07 3.2x10s 2.6x10* 1.4x10* 0.9X102 0.3X101
Fucidin Gel 4.8X107 4.1X106 3.1x10s 2.8x10s 3.2x10* 9.5X102
- 12 -
The heated area (%) of the wound on day 17 was 90.5 + 5.4 in Group 1 against 53.3 + 5.1 in Control and 78.7 + 6.1 in Group 2 (Fucidin Gel).
Similar reεultε were obtained for microbiological count. Initial microbe count waε IO6- IO7 cfu/g. Elimination of bacteria began from day 4 of treatment for all preparationε. With Abisil prepared as in Example 1, on day 6 the microbe count was 1.8 x 10 cfu/g compared with 4.8 x IO6 in controls and 3.5 x 104 in Fucidin-treated animals.
Cytological εtudy of wound exudate in animals before treatment εhowed about 96.6% of neutrophilε, with degenerated cytoplaεt. In all εampleε, a large number of microbial bodieε were εeen inside and outεide cellε, incompletely phagocytosed.
On day 2 of treatment there waε no εignificant difference between treatments. All cystograms were characterised as inflammatory. On day 12 in animals treated with Abisil, the content of neutrophils decreased to 55-60%; the number of macrophages increaεed. A εmall number of microbial bodieε were found, almoεt completely destroyed in phagocytes. In Fucidin-treated animals neutrophilε made up 75-80% and monocyteε, lymphocyteε and macrophages accounted for 5-10%.
In the Control Group a large number of microbial bodies were found outside cells. Neutrophils and macrophages were in degenerated and partly destroyed forms.
- 13 -
On day 17 in a group of animals treated with Abisil, the young cells of granulation tissue appeared: profibroblastε, fibroblaεt, polyblaεt macrophageε. No microbial bodieε, single neutrophilε.
A εimilar picture in treatment with Fucidin was observed on day 21 and on day 26-27 in the Control Group.
Example 2
Preparation Abisil waε obtained in the εame way aε Example 1 except that the fraction of ethereal oils containing monoterpenes was mixed with the capsular extract in the ratio 0.5 + 0.3:99.5 + 0.1 (0.5%), with subsequent dilution in vegetable oil in the ratio of 1:4 (20%) .
The efficacy of Abisil in compariεon with reference preparationε was studied in 3 groups of rabbits (6 rabbits per group) . Treatments were:
Group 1 - Abisil-l Group 2 - Fucidin gel
Group 3 - Untreated controlε
Before treatment, the wounds were purulent with an area of about 110cm2, and were characterised by edemaous, infiltrated edgeε, and hyperaemia of the εurrounding εkin. The base of the wound was covered with a depoεit of fibrin and had regions of necrosiε and purulent diεcharge.
- 14 -
Reεultε
In Group 1 (Abiεil) poεitive dynamicε of wound healing were observed on the 2nd day; edema and infiltration of the wound were reduced and hyperaemia had disappeared.
In Group 2 (Fucidin gel) signs of inflammation were clearly visible at this time. A conεiderable amount of fibrin depoεit, thick puε and necrotic tissue were found at the base of the wound.
In the untreated Control Group (Group 3) , abundant purulent discharge, haemorrhagic diatheεiε, edema and hyperaemia were obεerved at the baεe and edges of the wound.
In Group 1 (Abisil) , on days 4-6 of treatment, the count appeared clean from deposits of fibrin.
Necrotic tisεue in the wound waε absent and surrounding hyperaemia had disappeared.
Exudation inside the wound had become seropurulent.
In the Fucidin-treated animals (Group 2) , a moderate release of pus, slight edema and some necrotic masseε were obεerved.
On day 8 in the Abiεil-treated rabbitε, purulent and necrotic aεses had disappeared completely; the wound was filled with moiεt granulation tiεεue and there were areas of marginal epithelialisation. At the same time, in Group 2 residual necrotic masses and fibrin deposits
- 15 -
εtill remained; theεe could be removed mechanically during cleanεing of the wound.
On dayε 10-12 of observation in the Abisil- treated animals, the baεe of the wound was completely filled with granulation tiεεue with large areas of fibroεiε and marginal epithelialiεation. The size of the wound had decreased.
A similar picture was seen in Group 2 (Fucidin gel) on days 14-16 and day 17 in the Control Group.
On day 17 in the Control Group, the wound waε covered with a secondary crust and contraction of the wound incomplete. In the Abiεil-treated group, the wound was completely epithelialiεed, a εcar formed and at the edgeε of the wound, hair growth had occurred.
By day 19 in Abiεil-treated animalε, there waε complete wound healing with scar formation. All of the wound, except for a small area in the centre, was covered with hair. In Fucidin- treated animals a similar picture was observed 5- 6 days later, in control animals - 8-10 dayε later.
Comparison of the reεults on treatment of purulent wounds with Abisil and Fucidin gel confirmed the efficacy of Abisil compared with reference preparation, in terms of removing necrotic masses from purulent wounds, formation of granulation tissue and filling of the wound
- 16 -
cavitieε .
Reεultε are given in Tableε 2 and 3. On day 17 in the Abiεil-treated animalε 95.5 + 4.4% of wound εurface waε healed, compared with 53.3 +
5.1 in controlε and 89.4 + 5.3% in Fucidin group. The total time of wound healing in the Abisil- treated group waε 18.1 + 0.4 days, 21.8 ± 0.6 days in the Fucidin-treated animals and 26.1 + 1.5 in controls.
With Abisil prepared as in Example 1, microbial count in the wounds on day 6-8 was 1.8 x 102 cfu/g in the Abisil-treated group. 4.8 x 106 in controls and 3.5 x 10* in Fucidin-treated animals.
Cytological study of wound exudate of animals treated with Abisil on days 4-6 showed 70% of neutrophils together with macrophages, lymphocytes and fibroblasts. A proportion of the microbes were located inside cells.
On day 8 in the Abiεil-treated group, the number of neutrophils decreased to 50-60% and the number of macrophages increased. Only a few microbial bodies were found. In the Control Group on the same day, large numbers of neutrophils and microbial bodies located outside cells were observed. In the Fucidin-treated group the content of neutrophils was 75%.
On day 12, in the Abisil-treated group of animals, the content of neutrophils decreased to 40%. No microbial cells were found. A similar
- 17 -
picture waε observed on day 17 in Group 2 (Fucidin) and on dayε 22-24 in the Control Group.
Example 3
Abiεil waε obtained aε in Example 1 except that the monoterpene fraction was mixed with the capεular extract in the ratio of 1:99 (1%) with εubεequent dilution in vegetable oil 1:4 (20%).
The efficacy of Abiεil in comparison with reference preparations waε studied in 3 groups of rabbitε (6 rabbits per group) . Treatmentε were:
Group 1 - Abisil
Group 2 - Fucidin gel
Group 3 - Untreated controls
Before treatment, the woundε were purulent with an area of about 110cm2 and were characteriεed by edematouε, infiltrated edges and hyperaemia of the surrounding εkin. The base of the wound was covered with a deposit of fibrin and had regions of necrosis and purulent discharge.
On day 2 of the treatment with Abisil, the clinical picture was the same as in Example 2.
A significant difference was observed on days 12- 17 of observation. On day 12 the base of the wound was not completely filed with granulation.
The granulation tisεue became completely fibrotic on days 16-17. Epithelialiεation of the wound was completed on days 18-19. The scar was formed
- 18 -
in the same time.
Tables 2 and 3 show that on day 17, % of wound healing was 94.3 + 0.1 + 5.1 in control and 78.7 + 6.1 in the group treated with Fucidin gel. Microbe count εhowed a low number of microbeε already on day 6: 1.4 x 10* against 4.8 x IO6 in control and 3.5 x 10* in Fucidin-treated group. Cytological study on day 12 or treatment with Abiεil-1 εhowed an abundance of profibroblastε, polyblaεtε and macrophages. The number of neutrophils decreaεed to 44%. No microbe cellε were found.
Example 4
Female patient aged 33. Diagnoεiε: erysipelatous inflammation of right femur, bullous-necrotic form of plegmone of the right lower extremity.
Before the beginning of treatment with Abisil-1, the ointment "Levomicole" and a εurgical treatment such as opening, cleaning and drainage of plegmone were applied. However, the state of the patient did not improve. The body temperature increased to 37.8°C.
On the second day of treatment with Abisil-1 the condition of the patient improved; pain ceased, granulation of the wound began and body temperature dropped to normal. On day 5 of the treatment the granulation was significant and the edema began to decrease. On day 10 the wound was practically clean with granulation and epithelium.
- 19 -
The efficiency of treatment with Abisil-1 was high, no side effectε.
Example 5
Male patient aged 42. Diagnoεiε: post- infectional encephalopathia. Before the beginning of treatment with Abiεil-1, Vishnevεki liniment waε applied. After the beginning of treatment with Abiεil-1 the general condition of the patient, hiε sleep and appetite improved. Faεt cleaning, granulation and epithelialiεation of the wound waε obεerved. On day 5 of treatment edema and pain were absent and hypergranulation of the wound was observed.
The efficiency of treatment with Abisil-1 waε high, no εide effectε.
Example 6
Male patient aged 36. Diagnoεiε: abdominal trauma, rupture of εmall intestine. Diffuse fibrous purulent peritonitis, phlegmone of abdominal wall. Surgical treatment performed prior to treatment with Abisil: repair of εmall inteεtine, drainage of abdominal cavity. Medications: antibiotics, liniment "Levomicole". The general condition of the patient waε poor. From the beginning of treatment with Abiεil-1 the condition of the patient started to improve, body temperature decreased, the purulent discharge from the wound deceased and the size of the wound decreased. On day 2 a granulation appeared in the wound.
- 20 -
The efficiency of treatment with Abiεil-1 was high: fast cleaning, granulation and epithelialisation of the wound waε obεerved. No εide effects.
Thuε, a comparative εtudy of anti-inflammatory and wound-healing activity which took into account a clinical picture of the inflammatory proceεε and wound healing, microbe count from purulent wounds, time of wound healing and cytological εtudieε of the wound-healing proceεε εhowed that the propoεed preparation Abiεil-1 (vegetable oil εolution of capεular extract from Siberian Fir enriched with a fraction of monoterpeneε in the % ratio 19.5:0. l:rest) is a more active anti-inflammatory and wound-healing preparation (97.5 + 5.4% and 94.3 + 0.1 of wound healing till day 17 of treatment) than other Abiεil preparationε with different fractions of monoterpeneε 19.5:0.02: reεt and 19.5:02: reεt) - (90.5 + 5.4% and 94.3 ± 0.1% of wound healing till day 17 of treatment) and Fucidin gel (78.6 + 6.1% of wound healing till day 17 of treatment) . Alεo, Abiεil-1 applied over 7-10 dayε produceε faεt cleanεing of the wound from purulent diεcharge and necrotic aεses and stimulates reparative procesεeε when applied during Phaεeε I and II of the wound healing proceεε while being of low irritancy. Theεe propertieε are not typical for other known medial preparationε.
The natural capεular extract from Siberian Fir waε not used aε a comparative product becauεe the decreaεe of content of monoterpene fraction from 0.1% to 0.02% significantly reduceε the activity
- 21 -
of the preparation. (Tables 2 and 3) . It would not be reasonable to study the monoterpene fraction itself because it is very toxic and also because an increase of this fraction in preparation did not increase the activity of the latter.
Thus, an injection into the capsular extract of Siberian Fir of multicomponent fraction of monoterpenes, obtained by the fractional separation of capsular extract and a subsequent disεolution of enriched capsular extract in vegetable oil allows production of a preparation with high anti-inflammatory, anti-bacterial and wound healing activity.
Claims
1. A pharmaceutical preparation in the form of a concentrate which when diluted to an appropriate concentration, has anti-inflammatory, anti-bacterial and wound healing activity which preparation comprises a capsular extract of the Siberian fir Abies sibericus ledebur. and the monoterpene compounds from the ethereal oils of εaid capεular extract, εaid monoterpene compounds being present in an amount of about 0.1% to about 1.0% by volume.
2. A pharmaceutical preparation as claimed in claim 1 wherein said monoterpene compoundε are present in an amount of about 0.5% by volume.
3. A pharmaceutical preparation which compriseε a concentrate aε claimed in claim 1 or claim 2 diluted with a lipophilic solvent.
4. A pharmaceutical preparation as claimed in claim 3 which is diluted with a vegetable oil.
5. A pharmaceutical preparation as claimed in claim 3 or claim 4 which is diluted with a vegetable oil at a ratio of preparation to oil of 1:4.
6. A pharmaceutical preparation as claimed in claim 4 or claim 5 wherein said vegetable oil is sunflower oil.
7. A preparation as claimed in any preceding claim in which the monoterpene compounds are selected from tricyclene, limonene and camphene. - 23 -
8. Use of a capsular extract of the Siberian fir Abies sibericuε ledebur. when in combination with the monoterpene compoundε from the ethereal oils of said capsular extract in an amount of 0.1 to 1% by volume, in the manufacture of a medicament for healing woundε.
9. A method of preparing a pharmaceutical preparation which compriεeε the steps of:-
(a) obtaining an extract from the capsules of the Siberian fir, Abies sibericus ledebur.,
(b) filtering said extract,
(c) diεtilling εaid extract for up to approximately 12 hours and collecting the distillate and,
(d) mixing said distillate with undiεtilled capsular extract in such volumetric amounts as to produce a preparation in which said diεtillate is about 0,1 to about 1.0% by volume.
10. A method as claimed in claim 9 wherein said distillate is added in sufficient amount to produce a preparation in which said distillate is about 0.5% by volume.
11. A method aε claimed in claim 9 or claim 10 wherein εaid diεtillate comprises monoterpene compoundε.
12. A method aε claimed in any one of claimε 9, 10, or 11 compriεing the additional εtep of diluting - 24 -
said preparation of step (d) with a lipophilic εolvent.
13. A method aε claimed in claim 12 wherein εaid lipophilic εolvent iε a vegetable oil and εaid preparation iε diluted to a ratio of preparation to oil of 1:4.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU51558/96A AU5155896A (en) | 1995-06-28 | 1996-03-29 | Pharmaceutical composition for wound healing |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU95109894 | 1995-06-28 | ||
| RU95109894/14A RU2054945C1 (en) | 1995-06-28 | 1995-06-28 | Agent showing antiinflammatory, antibacterial and wound-healing activities |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1997001347A1 true WO1997001347A1 (en) | 1997-01-16 |
Family
ID=20168879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/GB1996/000756 WO1997001347A1 (en) | 1995-06-28 | 1996-03-29 | Pharmaceutical composition for wound healing |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU5155896A (en) |
| RU (1) | RU2054945C1 (en) |
| WO (1) | WO1997001347A1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2762994A1 (en) * | 1997-05-12 | 1998-11-13 | Jacques Vernin | COMPOSITION BASED ON PLANT EXTRACTS AND ESSENTIAL OILS FOR USE IN THERAPEUTICS, COSMETICS AND DIETETICS |
| JP2016094354A (en) * | 2014-11-12 | 2016-05-26 | 三笠製薬株式会社 | Anti-inflammatory external preparation |
| JP2019104764A (en) * | 2014-11-12 | 2019-06-27 | 三笠製薬株式会社 | Anti-inflammatory external preparation |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009113902A1 (en) | 2008-03-14 | 2009-09-17 | Общество С Ограниченной Ответственностью "Инитиум-Фарм" | Antitumoral terpenoid pharmaceutical composition 'abisilin' exhibiting angiogenesis-inhibiting action |
| WO2013176564A1 (en) * | 2012-05-25 | 2013-11-28 | Общество С Ограниченной Ответственностью "Инитиум-Фарм" | Terpenoid agent for the prophylaxis and treatment of atherosclerosis and the correction of metabolic syndrome |
| KR101597004B1 (en) * | 2013-07-25 | 2016-02-23 | 씨제이헬스케어 주식회사 | Pharmaceutical combination comprising sustained-release type metformin and immediate-release type HMG-CoA reductase inhibitor |
| RU2647836C1 (en) * | 2016-10-27 | 2018-03-19 | Митче Анастасия Евгеньевна | Composition for disinfection and aromatization of air |
| RU2765414C1 (en) * | 2020-09-30 | 2022-01-31 | Ооо "Инитиум-Фарм" | Method for stimulating mitophagy and autophagy in cells, method for stimulating autophagy or mitophagy for treating a condition associated with mitochondrial dysfunction |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1727773A1 (en) * | 1990-03-11 | 1992-04-23 | Сибирский научно-исследовательский институт лесной промышленности | Feed additive for young pigs |
-
1995
- 1995-06-28 RU RU95109894/14A patent/RU2054945C1/en active
-
1996
- 1996-03-29 AU AU51558/96A patent/AU5155896A/en not_active Abandoned
- 1996-03-29 WO PCT/GB1996/000756 patent/WO1997001347A1/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1727773A1 (en) * | 1990-03-11 | 1992-04-23 | Сибирский научно-исследовательский институт лесной промышленности | Feed additive for young pigs |
Non-Patent Citations (1)
| Title |
|---|
| DATABASE WPI Section Ch Week 9314, Derwent World Patents Index; Class B04, AN 93-115247, XP002009309 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2762994A1 (en) * | 1997-05-12 | 1998-11-13 | Jacques Vernin | COMPOSITION BASED ON PLANT EXTRACTS AND ESSENTIAL OILS FOR USE IN THERAPEUTICS, COSMETICS AND DIETETICS |
| WO1998051320A1 (en) * | 1997-05-12 | 1998-11-19 | Jacques Vernin | Composition based on plant and essential oil extracts, usable in therapy, cosmetics and dietetics |
| US6200572B1 (en) | 1997-05-12 | 2001-03-13 | Jacques Vernin | Capsule containing plant extracts and microencapsulated essential oils |
| JP2016094354A (en) * | 2014-11-12 | 2016-05-26 | 三笠製薬株式会社 | Anti-inflammatory external preparation |
| JP2019104764A (en) * | 2014-11-12 | 2019-06-27 | 三笠製薬株式会社 | Anti-inflammatory external preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| RU95109894A (en) | 1997-06-10 |
| AU5155896A (en) | 1997-01-30 |
| RU2054945C1 (en) | 1996-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0060553B1 (en) | Preparation for treating outer skin wounds and process for manufacturing said preparation | |
| CN111202822A (en) | Gynecological external antibacterial spray and preparation method thereof | |
| DASOPANG et al. | Hispathology And Effectiveness Of Wound Healing Cream Karo Oil Herbal Extract On Male Mice In North Sumatra, Indonesia | |
| BRPI1013222B1 (en) | composition consisting of an isolated fraction of mastic gum obtained from pistacia lentiscus l. | |
| Chhetri et al. | Formulation and evaluation of antimicrobial herbal ointment | |
| WO1997001347A1 (en) | Pharmaceutical composition for wound healing | |
| JPH06279256A (en) | Skin external preparation | |
| US7258876B2 (en) | Topical composition for treating infectious conditions of skin and mucosa | |
| CN105267106A (en) | Mongolian dandelion herb traditional Chinese medicine hand sanitizer and preparation method thereof | |
| WO2016088093A1 (en) | Propolis-silver preparation accelerating the regeneration of soft tissues and method of obtaining thereof | |
| Nsofor et al. | Evaluation of antibacterial activity of Aloe vera extract on some bacterial pathogens | |
| US5635184A (en) | Essential oil composition with bactericide activity | |
| CN112245325A (en) | Health-care antibacterial gel and preparation method thereof | |
| CN116747152A (en) | Preparation method and application of recombinant III type humanized collagen liquid dressing | |
| Chandrasekar et al. | Formulation and Evaluation of a Poly Herbal Anti-acne gel | |
| CN112316012A (en) | Moisturizing antibacterial gel and preparation method thereof | |
| RU2221550C1 (en) | Medicinal preparation for treatment of bacterial eczema, paraproctitis, burn, trophic ulcer and other sluggish wounds and method for preparing preparation | |
| Gandomkar et al. | Development of an anti-acne cream based on natural oils: Investigation of the effect of ingredients on rheology, texture properties, and physical stability | |
| KR101914568B1 (en) | Cosmetic Composition For A Alleviating Atopic Dermatitis And Pruritis Using By Bioconversion Of The Extracts and Method For Manufacturing the same | |
| Masyudi et al. | Effectiveness of gel formulation of capa leaf (Blumea balsamifera L.) on wound healing in white rats | |
| CN113967184B (en) | Antibacterial and anti-inflammatory compound phellodendron bark composition, preparation method thereof and cosmetic containing same | |
| CH677878A5 (en) | ||
| Khadir et al. | Inhibitory Effect of Myrtus communis L. and Syzygium aromaticum L. Extracts on the Growth of Staphylococcus aureus Isolated from Foot Ulcers of Diabetic Patients | |
| Alqudah et al. | Comparison of Antibacterial and Antioxidant Activities of Ethanolic Extracts of Four Plant Species Selected from South of Saudi Arabia | |
| CN107362310A (en) | It is a kind of to be used to repair Baicao Fuyanqing preparation of vagina environment and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AT AU BB BG BR CA CH CN CZ DE DK EE ES FI GB HU IS JP KE KP KR LK LR LS LT LU LV MG MK MN MW MX NO NZ PL PT RO SD SE SG SI SK TR TT UG US VN |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| CFP | Corrected version of a pamphlet front page | ||
| CR1 | Correction of entry in section i | ||
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: CA |